Name

FIFARMA

Legal name

Federación Latinoamericana de la Industria Farmacéutica, A.C.

Website

https://fifarma.org

Company type

Private

Founded year

1962

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Fees: Annual membership dues from 19 pharmaceutical member companies and 11 local industry associations across Latin America and the Caribbean.
2. Publications and Reports: Studies and reports on health innovation, regulatory policy, and pharmaceutical access distributed to industry stakeholders, governments, and academic institutions. Reports recorded over 1,500 downloads.
3. Events and Webinars: Organizes regional events, webinars, and training programs including the LATAM ICH webinar series and Academia FIFARMA training for over 250 people annually.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

FIFARMA is a regional pharmaceutical industry federation that develops evidence-based research, policy studies, and proprietary data platforms (including the W.A.I.T. Indicator and Health Innovation Outlook) measuring access to innovative medicines, regulatory reliance, and health innovation across Latin America and the Caribbean. It convenes 19 research-based pharmaceutical member companies and 11 local industry associations to influence health policy, support regulatory harmonization, and publish comparative country-level studies for governments, regulators, and researchers.

Product overview

FIFARMA is a federation of pharmaceutical research and development companies operating across Latin America and the Caribbean. Rather than offering a unified software product, FIFARMA provides a portfolio of research publications, monitoring platforms, educational programs, and technical resources focused on health innovation, regulatory harmonization, and patient access to medicines. The core offerings include the Patient W.A.I.T. Indicator and Health Innovation Outlook reports, the Regulatory Observatory (OPRES) monitoring platform, the Academia FIFARMA training program, and various best practices guides including the Pharmacovigilance LatAm Handbook and Clinical Research Report. These products work together to support evidence-based decision-making, regulatory cooperation, and health system strengthening across the region.

Differentiator

Problem solved

Functional benefit

Brands

• Observatorio Regional FIFARMA: Data platform providing health and innovation indicators for Latin American countries
• Health Innovation Outlook
• W.A.I.T. Indicator
• FIFARMA Patient W.A.I.T. Indicator
• OPRES
• Pharmacovigilance LatAm Handbook
• LATAM ICH Webinar Series
• Academia FIFARMA
• Latam Health Champions

Products and services

• Patient W.A.I.T. Indicator Annual report measuring waiting times for access to innovative medicines across Latin American countries, developed in collaboration with IQVIA, analyzing availability and accessibility of treatments approved by FDA and EMA. Intended for pharmaceutical companies, regulators, ministries of health, and patient advocacy groups.
• Health Innovation Outlook Comprehensive study analyzing 55 indicators comparing health and innovation performance across 11 Latin American countries including Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Panama, Peru, Dominican Republic, and Uruguay. Used for cross-country benchmarking and policy planning.
• Biopharmaceutical Competitiveness & Investment Report (BCI) Report analyzing the investment climate for the biopharmaceutical sector in Latin America, prepared by Pugatch Consilium, evaluating market competitiveness and investment conditions across 10 economies. Intended for industry executives, investors, and policymakers.
• Pharmacovigilance LatAm Handbook Technical guide strengthening risk management for patient protection, providing comparative analysis of pharmacovigilance requirements across seven Latin American countries. For regulatory affairs professionals and pharmacovigilance teams.
• Latin America Clinical Research Report Report with recommendations based on best practices for clinical research in Latin America, developed in collaboration with CIRS (Centre for Innovation in Regulatory Sciences). Intended for sponsors, CROs, regulators, and investigators.
• Health Budget Practices Analysis Analysis of health budget planning, prioritization, allocation, and management practices across eight Latin American countries (Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Peru), prepared by Duke University Global Health Institute.
• Time to Vax First regional study analyzing access to and availability of innovative vaccines across twelve Latin American countries, evaluating 29 vaccines approved globally between 2010 and 2025.
• Regulatory Observatory (OPRES) Monitoring platform for health policies and regulations in Latin America, developed with INNOS, providing dashboards, country profiles, and policy analysis for governments and industry stakeholders.
• Academia FIFARMA Training and educational initiative providing capacity-building on pharmaceutical policy, regulatory affairs, and health innovation for professionals across Latin America. Trained over 250 people in 2025.
• Regulatory Reliance Monitoring Center Monitoring initiative studying regulatory reliance implementation across Latin America, analyzing tools that leverage international regulatory authority assessments to accelerate patient access to treatments.
• LatAm ePI Playbook Comprehensive guide for Electronic Product Information (ePI) implementation in Latin America and the Caribbean, developed in collaboration with EFPIA, examining current status and future prospects of digital product information.

Quantifiable outcome

• Patients in Latin America wait an average of 4.7 years to access innovative treatments approved by FDA or EMA
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and secondary.

• IQVIAcoreStrategic or Co-development Partner · 1 January 2025Multi-year collaboration developing the W.A.I.T. (Waiting to Access to Innovative Therapies) Indicator, the leading regional benchmark measuring access to innovative medicines. Also collaborated on the FIFARMA Time to Vax 2025 study analyzing vaccine access across 12 Latin American countries.
• Pugatch ConsiliumcoreStrategic or Co-development Partner · 1 January 2025Collaboration on the Biopharmaceutical Competitiveness and Investment (BCI) Report 2025, analyzing the investment environment and regulatory landscape for pharmaceuticals across 10 Latin American economies.
• Duke University Global Health InstitutecoreStrategic or Co-development Partner · 1 January 2025Collaboration on Analysis of Health Budget Practices in 8 Latin American countries, examining how health resources are planned, prioritized, allocated, and managed across Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, and Peru.
• INNOS (Colombia)coreStrategic or Co-development Partner · 1 January 2025Collaboration on the Regional Observatory including the Health Innovation Outlook study and the Observatory of Regulatory Best Practices (OPRES). Joint initiative on regulatory policy monitoring and analysis for Latin America.
• CIRS (Centre for Innovation in Regulatory Sciences)secondaryStrategic or Co-development PartnerCollaboration on clinical research best practices recommendations for Latin America, supporting regulatory convergence and reliance implementation.
• EFPIA (European Federation of Pharmaceutical Industries and Associations)secondaryStrategic or Co-development PartnerCollaboration on the LatAm Playbook for Electronic Product Information (ePI) Implementation, providing guidance on digital transformation of product information in the region.
• University of São Paulo (USP) - Institute of International RelationssecondaryStrategic or Co-development PartnerResearch collaboration on health investment analysis covering Argentina, Brazil, Chile, Colombia, Mexico, and Peru, resulting in a comprehensive publication on health financing in the region.
• IFPMA (International Federation of Pharmaceutical Manufacturers & Associations)coreStrategic or Co-development PartnerGlobal industry federation partnership; FIFARMA's Executive Director Yaneth Giha serves as Vice Chair of the IFPMA Governing Board, connecting regional work with global pharmaceutical policy frameworks.
• Movement Health 2030secondaryStrategic or Co-development PartnerCollaboration on digital health transformation in Latin America, working with over 25 institutions to foster connectivity and share best practices across the region.
• Pan American Health Organization (PAHO)coreStrategic or Co-development PartnerOngoing collaboration on regulatory harmonization, pharmacovigilance strengthening, and health technology assessment supporting regional health system development.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• PhRMA (Pharmaceutical Research and Manufacturers of America): US federation representing research-based pharmaceutical companies. Same advocacy and research-publishing model as FIFARMA, focused on US policy environment rather than LatAm; the benchmark trade body FIFARMA is most often compared to in thought-leadership output.
• CAEMe (Cámara Argentina de Empresas de Medicina Privada / Cámara Argentina de Especialidades Medicinales): Argentine pharma industry chamber and FIFARMA member. National advocacy body for research-based pharma, peer in function though smaller in footprint than FIFARMA.
• JPMA (Japan Pharmaceutical Manufacturers Association): Japanese pharmaceutical manufacturers' association. National-federation model representing R&D pharma, with parallel function to FIFARMA on policy advocacy, industry data, and global regulatory engagement.
• INTERFARMA (Associação da Indústria Farmacêutica de Pesquisa): Brazilian research-based pharma industry association and a FIFARMA member. Operates the same advocacy/regulatory model at national scope; most direct comparator because it represents one of FIFARMA's largest constituent markets.
• AFIDRO (Asociación de Laboratorios Farmacéuticos de Investigación y Desarrollo): Colombian pharma research-and-development industry association and FIFARMA member. Operates the same national advocacy model as other FIFARMA constituent associations like ALAFARPE and CAEMe.
• EFPIA (European Federation of Pharmaceutical Industries and Associations): European pharma industry federation — the closest geographic parallel to FIFARMA's regional federation model. EFPIA and FIFARMA have already co-developed the LatAm ePI Playbook, evidencing direct peer overlap in mission and partnerships.
• IFPMA (International Federation of Pharmaceutical Manufacturers & Associations): Global federation of research-based pharma companies and associations. FIFARMA operates as a regional member within IFPMA's network, with FIFARMA's Executive Director sitting on IFPMA's Governing Board. Same federation model, but global rather than regional scope.
• ALAFARPE (Asociación Nacional de Laboratorios Farmacéuticos del Perú): Peruvian pharma industry association and FIFARMA member. Same national-federation advocacy model serving multinational R&D pharma; FIFARMA is essentially the umbrella for ALAFARPE and similar bodies.

Broad incumbents

• BIO (Biotechnology Innovation Organization): US-based trade association for the biotechnology industry, including therapeutics, diagnostics, and agricultural biotech. Broader scope than FIFARMA but operates a similar federation/trade-body model with policy advocacy and member publications.
• Medicines Australia: Australian pharma industry association representing research-based companies. Same regional federation model for a different geography; useful as a scaling/operating precedent for FIFARMA.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCNL54kZ6qGEhANloIvp2juw?view_as=subscriber
• LinkedInlinkedin.com/company/fifarma
• Instagraminstagram.com/fifarmalatam

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FIFARMA